The US Food and Drug Administration (FDA) has approved the first product containing hematopoietic progenitor cells from human umbilical cord blood.
Known as HEMACORD, the therapy is indicated for use in hematopoietic stem cell transplantation procedures in patients with blood system disorders, including children. Cord blood transplants are used routinely to treat patients with certain blood cancers and some inherited metabolic and immune system disorders.
“The use of cord blood hematopoietic progenitor cell therapy offers potentially life-saving treatment options for patients with these types of disorders,” said Karen Midthun, MD, director of the FDA Center for Biologics Evaluation and Research, in a statement.
Voelker R. FDA Grants Approval for First Cord Blood Product. JAMA. 2011;306(22):2442. doi:10.1001/jama.2011.1759
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: